Cargando…

Clinical and prognostic analyses of 110 patients with N(3) nasopharyngeal carcinoma

OBJECTIVE: To analyze the clinical outcome and prognostic factors of N(3) nasopharyngeal carcinomas (NPCs), provide a basis for rational treatment and improve the cure rate. METHODS: A total of 110 patients with a pathologically confirmed diagnosis of N(3) (NPC 2008 stage in China) NPC from our hosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jing, Liu, Tongxin, Sun, Quanquan, Hu, Fujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310544/ https://www.ncbi.nlm.nih.gov/pubmed/30544441 http://dx.doi.org/10.1097/MD.0000000000013483

Ejemplares similares

Neoadjuvant Chemotherapy with Fluorouracil plus Nedaplatin or Cisplatin for Locally Advanced Nasopharyngeal Carcinoma: a Retrospective Study
por: Liu, Tongxin, et al.
Publicado: (2018)

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
por: Liu, Tongxin, et al.
Publicado: (2018)

Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma
por: Chen, Jing, et al.
Publicado: (2020)

miR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1
por: SUN, QUANQUAN, et al.
Publicado: (2015)

Outcome and long-term efficacy of four facio-cervical fields conformal radiotherapy for nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2016)

Bioinformatic identification of candidate biomarkers and related transcription factors in nasopharyngeal carcinoma
por: Ye, Zhimin, et al.
Publicado: (2019)

Addition of 5-fluorouracil to docetaxel/cisplatin does not improve survival in locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Fangzheng, et al.
Publicado: (2017)

Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Fangzheng, et al.
Publicado: (2020)

Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis
por: Wang, Fangzheng, et al.
Publicado: (2020)

Addition of chemotherapy to intensity-modulated radiotherapy does not improve survival in stage II nasopharyngeal carcinoma patients
por: Fangzheng, Wang, et al.
Publicado: (2018)

Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
por: Wang, Fangzheng, et al.
Publicado: (2018)

Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience
por: Wang, Fangzheng, et al.
Publicado: (2017)

miR-195 is a key regulator of Raf1 in thyroid cancer
por: Wang, Fangzheng, et al.
Publicado: (2015)

Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma
por: Wang, Fangzheng, et al.
Publicado: (2018)

Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis
por: Fangzheng, Wang, et al.
Publicado: (2017)

Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution
por: Fangzheng, Wang, et al.
Publicado: (2018)

Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
por: Fangzheng, Wang, et al.
Publicado: (2019)

Screening of significant biomarkers with poor prognosis in hepatocellular carcinoma via bioinformatics analysis
por: Sun, Quanquan, et al.
Publicado: (2020)

Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience
por: Liu, Tongxin, et al.
Publicado: (2020)

Prognostic Value of Clinical Biochemistry-Based Indexes in Nasopharyngeal Carcinoma
por: Zeng, Xiaojiao, et al.
Publicado: (2020)

Comparison of radiomics tools for image analyses and clinical prediction in nasopharyngeal carcinoma
por: Liang, Zhong-Guo, et al.
Publicado: (2019)

Prognostic Value of Lymph Node Necrosis at Different N Stages in Patients with Nasopharyngeal Carcinoma
por: Fu, Yue-Chun, et al.
Publicado: (2023)

Diagnostic and Prognostic Potential of Circulating and Tissue BATF2 in Nasopharyngeal Carcinoma
por: Cui, Zhaolei, et al.
Publicado: (2021)

Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma
por: Liu, Zhiqiang, et al.
Publicado: (2018)

Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics
por: Li, Jianpei, et al.
Publicado: (2018)

Prognostic value of tumor burden in nasopharyngeal carcinoma
por: Chen, Chuanben, et al.
Publicado: (2018)

Prognostic value of neutrophils for patients with nasopharyngeal carcinoma
por: Chen, Lisha, et al.
Publicado: (2021)

The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients
por: Liu, Li-Ting, et al.
Publicado: (2018)

Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma
por: E. A. R., Engku Nur Syafirah, et al.
Publicado: (2020)

Prognostic factors in metastatic nasopharyngeal carcinoma
por: Toumi, Nabil, et al.
Publicado: (2020)

CXCL12 genetic variants as prognostic markers in nasopharyngeal carcinoma
por: Chen, Ruiwan, et al.
Publicado: (2015)

Arterial interventional chemotherapy and IMRT with concurrent chemotherapy for nasopharyngeal carcinoma with intracranial involvement
por: FEN, XINGLAI, et al.
Publicado: (2013)

Transcriptomic Analyses Reveal Gene Expression Profiles and Networks in Nasopharyngeal Carcinoma
por: Zhou, Yaqi, et al.
Publicado: (2021)

Clinical Characteristics and Prognostic Factors of Early and Late Recurrence After Definitive Radiotherapy for Nasopharyngeal Carcinoma
por: Li, Feng, et al.
Publicado: (2020)

Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma
por: Zhu, Jing, et al.
Publicado: (2022)

The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal carcinoma patients
por: Long, Guoxian, et al.
Publicado: (2021)

Prognostic value of TIGAR and LC3B protein expression in nasopharyngeal carcinoma
por: Wei, Min, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d60j7vp2k07eoq6b6uhasccu7v